White papers

External Control Arms (ECA) address some of the practical, ethical and cost challenges of recruiting in-trial randomized control arms. Yet ECAs have their own limitations.

Nova’s modeling and simulation approach combines mathematical models of diseases and treatments with virtual patients into an integrated clinical trial simulation platform called jinkō.

In silico is emerging as the 3rd pillar of the drug R&D paradigm, in support of - not a full substitute to - more conventional in vitro and in vivo exploration and evidence-generation techniques.